Analysis of archived database to check correlation between CANscript test results and actual clinical outcome in cancer subjects

Not Applicable

• Conditions: Health Condition 1: C00-D49- NeoplasmsHealth Condition 2: null- Solid cancer

• Registration Number: CTRI/2017/12/010730
• Lead Sponsor: Mitra RxDx India Pvt Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1 CANscript test report for solid cancers such as head and neck colorectal gastrointestinal breast ovary lung etc

2 CANscript results with M-score available for at least 1 tested arm

3 Availability of clinical outcome data in terms of tumor responses for respective CANscript tested

Exclusion Criteria

(1) No specific exclusion criteria can be defined for the retrospective analysis

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Positive and negative prediction rate in overall and each cancer type population <br/ ><br>2. Percentage of correctly identified clinical responder and nonresponders, <br/ ><br>in overall and each cancer type populationTimepoint: [6 weeks]

Secondary Outcome Measures

Name	Time	Method
Compare positive, negative predictive values, sensitivity and <br/ ><br>specificity, in overall and each cancer type population using cohort as cytotoxic and cytostatic class of anti-cancer drugsTimepoint: [6 weeks];Sensitivity and specificity rate in overall and each cancer type <br/ ><br>populationTimepoint: [6 weeks];Summarize demographics (male, female, age, etc), cancer type and stages, drugs tested â?? alone, combinations, classes as <br/ ><br>chemotherapy, targeted (small molecules, biologicals, etc) and cytotoxic / cytostatic drugsTimepoint: [6 weeks]